Sermorelin vs Tesamorelin: GHRH(1-29) and the Stabilized GHRH Analog

The short version

Sermorelin vs tesamorelin is a comparison within one family. Both are GHRH analogs — both press the same pituitary 'release growth hormone' button. Sermorelin is the plain, short-lived version of the natural sequence. Tesamorelin is a stabilized, longer-lasting redesign, and it is the one that carries the strongest body-fat and cognition trial data. So when you read claims about sermorelin 'burning fat' or 'sharpening the mind,' most of that hard evidence actually comes from tesamorelin. This page keeps the two molecules separate and points each finding at the molecule that earned it.

Same drug class, two different molecules

Sermorelin and tesamorelin both belong to the GHRH-analog class and both act on the GHRH receptor ^[1]. Sermorelin is the native amidated GHRH(1-29) — short-acting, with a ~10-12 minute plasma half-life ^[3]. Tesamorelin is a stabilized synthetic GHRH analog (it carries a modification that resists rapid breakdown) and is FDA-approved for HIV-associated lipodystrophy. The shared mechanism is why findings get blurred across the two; the structural difference is why their evidence bases are not interchangeable.

The practical consequence for this record: several of the most-cited GHRH-axis outcomes — visceral-fat reduction, the large IGF-1 rise, the cognition signal — were generated with tesamorelin, not native sermorelin. Below, each is attributed to the molecule that produced it.

Body composition: where the strongest data actually come from

GHRH-axis stimulation can change body composition, but the strongest controlled data come from the stabilized analog. Tesamorelin significantly reduced visceral adipose tissue versus placebo in HIV-associated fat accumulation and in obese subjects with reduced GH. In the cognition trial discussed below, the GHRH analog also reduced percent body fat by 7.4% over 20 weeks ^[11]. Pulsatile GH contributes to fasting lipolysis as a general mechanism. Direct sermorelin fat-loss evidence in otherwise healthy adults is limited — which is the gap that anti-aging marketing tends to paper over.

IGF-1 and cognition: the tesamorelin trial

In a 20-week randomized, double-blind, placebo-controlled trial of 152 older adults (66 with mild cognitive impairment), a daily GHRH analog (tesamorelin, 1 mg/day before bedtime) had a favorable effect on cognition — executive function P=0.005 — while raising IGF-1 by 117% within the physiologic range and reducing percent body fat by 7.4% ^[11]. Adverse events were mild (NCT00257712, the SMART trial). This is the highest-quality cognition-and-IGF-1 record in the GHRH-analog literature, and it used tesamorelin — a point this comparison keeps explicit so the result is not silently reassigned to native sermorelin.

GH pulsatility and insulin sensitivity

A GHRH analog altered endogenous GH pulsatility and affected insulin sensitivity in healthy men, showing that GHRH-axis stimulation can modulate both GH secretory dynamics and glucose handling ^[12]. In the older-men sermorelin study, by contrast, 14 days of GHRH(1-29) raised GH and IGF-1 with no effect on fasting glucose ^[5]. The records are complementary rather than contradictory, but they were produced with different molecules and durations, and this page tags them accordingly.

Does sermorelin reduce body fat?

GHRH-axis stimulation can change body composition: the stabilized GHRH analog tesamorelin significantly reduced visceral adipose tissue versus placebo in HIV-associated fat accumulation, and pulsatile GH contributes to fasting lipolysis ^[11]. Direct sermorelin fat-loss evidence in healthy adults is limited.

Is sermorelin effective for weight loss?

The strongest body-composition data come from the related analog tesamorelin (visceral-fat reduction in HIV lipodystrophy and in obese subjects with reduced GH) ^[11]. Anti-aging and weight-loss marketing for sermorelin itself outpaces the rigorous evidence ^[2].